Merck brand relaunched
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the relaunch of its brand identity. The fundamental revision of the visual appearance as well as the introduction of a new logo reflect the transformation into a global science and technology company. At the same time, the brand architecture at business level has been simplified. Outside the United States and Canada, the company will operate uniformly as Merck.
Bristol-Myers Squibb's Opdivo (nivolumab) receives expanded FDA approval in previously-treated metastatic non-small cell lung cancer (NSCLC)
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR mutation or ALK translocation should have disease progression on appropriate targeted therapy prior to receiving Opdivo.
Roche's ocrelizumab first investigational medicine to show positive pivotal study results in both relapsing and primary progressive forms of multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced data from three positive, pivotal Phase III studies of ocrelizumab in people with relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). Data from two identical studies (called OPERA I and OPERA II) in people with relapsing MS, which affects approximately 85 percent of people with MS at the time of diagnosis, showed ocrelizumab was superior to interferon beta-1a (Rebif®), a well-established MS therapy, in reducing the three major markers of disease activity over the two-year controlled treatment period.
Johnson & Johnson announces completion of Cordis divestiture to Cardinal Health
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) has announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments. The Cordis business is a global leader in the development and manufacture of interventional vascular technology and generated net revenues of approximately $780 million in 2014.
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
- Details
- Category: Novartis
Novartis announced today a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya® (fingolimod). The analysis evaluated the proportion of Gilenya patients with relapsing multiple sclerosis (RMS) achieving 'no evidence of disease activity' (NEDA-4) every year over seven years[1].
Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has completed the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax. "The addition of Nimenrix and Mencevax helps us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide," said Susan Silbermann, president and general manager, Pfizer Vaccines.
Genzyme introduces "vs.MS," a global initiative aimed at uncovering the often unspoken challenges of MS to drive better informed care
- Details
- Category: Genzyme
Genzyme, a Sanofi company, today announced a new global initiative, vs.MS, that is designed to raise awareness of the often unspoken emotional and physical burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. To better understand the full burden associated with RMS, Genzyme fielded a global survey among more than 1,500 people living with RMS and their care partners across seven countries.
More Pharma News ...
- New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
- New Roche Esbriet data show clinical benefits of continued and long-term treatment in patients with idiopathic pulmonary fibrosis (IPF)
- Merck's Consumer Health business counts on Latin America for growth
- Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
- Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
- Bristol-Myers Squibb and Moffitt Cancer Center enter into a collaboration agreement
- Lilly Diabetes launches new Disney book for families affected by type 1 diabetes